On the Horizon: New Options for Treating Presbyopia

Supported by an unrestricted medical education grant from AbbVie.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Differentiate the underlying mechanisms of presbyopic changes.
• Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting options.
• Distinguish among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action.
• Explain how presbyopia-correcting drops are likely to affect categories of patients based on individual characteristics.
• Describe the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.

Accreditation and Designation Statement

Sponsored by

 

Credit Designation Statement
Evolve Medical Education LLC (Evolve) is an approved COPE administrator.

This activity, COPE Activity Number 123023, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1.25 hours CE. 

Course # 75786-AS
Activity # 123023

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Milton M. Hom, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/AbbVie, Eyenovia, Novartis, and Visus.Grant/Research Support: Allergan/AbbVie, Eyenovia, Novartis, and Vyluma. Speaker’s Bureau: Allergan/AbbVie.

Marc Bloomenstein, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, BioTissue, Johnson & Johnson Vision, Kala Pharmaceuticals, Ocusoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, and Sun.

April Jasper, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Eyenovia, Sun Pharmaceutical Industries, and Visus. Grant/Research Support: Alcon Vision.

The Evolve staff and planners have no financial relationships with commercial interests.
Mark Goerlitz-Jessen, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or AbbVie.